Boehringer Ingelheim Venture Fund
boehringer-ingelheim-venture.com Direct + LP
Boehringer Ingelheim Venture Fund is the corporate venture capital arm of Boehringer Ingelheim, investing in early-stage biotech and digital health companies. It focuses on first-in-class therapeutics and platforms, with a global presence in Europe, the US, and China.
Boehringer Ingelheim Venture Fund is a corporate venture arm headquartered in Ingelheim, Germany, founded in 2010. It invests both directly in companies and in funds as a limited partner, from seed to Series A, in cancer, regenerative medicine, Auto-immunity and digital solutions. €350M under management and 70 portfolio companies, as it reports.
“We invest in pioneering science that aims to redefine the standard of care and bring new medicines to patients.”
— Boehringer Ingelheim Venture Fund, own website
- Layer
- Direct + LP
- Headquarters
- Ingelheim, Germany
- Invests in
- EU, US, China
- Sectors
- Cancer, Regenerative medicine, Auto-immunity, Digital solutions, Infectious disease
- Founded
- 2010
- Assets under management
- €350M
- Portfolio
- 70 companies
Team, as Boehringer Ingelheim Venture Fund publishes it
- Detlev Mennerich Global Head of BI Venture Fund
- Sebastian Kreuz Head of BI Venture Fund EU
- Manuel Baader Investment Manager
- Philipp Müller Investment Manager
- Jennifer Gantner Backoffice
- Mia Hu Investment Manager
- Oliver Reuß Investment Manager
- Paul Nicklin Investment Manager
- Julia Kaufman Investment Manager
- Kevin White Investment Manager
- Maximilian Stöhr Head of Legal Boehringer Ingelheim Venture Fund
- Grace Jin Legal
Names and roles exactly as listed on boehringer-ingelheim-venture.com. Nothing else about these people is recorded.
Most shared portfolio companies with
Derived from portfolio pages both investors publish themselves: each pair below lists at least one company in common. 54 investors with a shared portfolio company. A shared company is not proof they invested together in the same round.
- Kurma Partners 5 shared companies: tacalyx.com, evlabio.com, imchecktherapeutics.com, nuevocor.com…
- coparion 3 shared companies: abalos-tx.com, heparegenix.com, tacalyx.com
- Andera Partners 2 shared companies: agomab.com, imchecktherapeutics.com
- Omnes Capital 2 shared companies: agomab.com, diogenx.com
- Creathor Ventures 2 shared companies: tacalyx.com, acousia.com
- Gemma Frisius Fund 2 shared companies: obulytix.com, rwdtx.com
- Avalon BioVentures Management, LLC 2 shared companies: biospace.com, boehringer-ingelheim.com
- Epidarex Capital 2 shared companies: libratherapeutics.com, topas-therapeutics.com
- Portfolia Venture Management, LLC 2 shared companies: xcures.com, wellthapp.com
- Delos Capital 2 shared companies: rgentatx.com, strm.bio
and 44 more — the graph.
Where this comes from
Every fact above was read from a page Boehringer Ingelheim Venture Fund publishes itself. Nothing is taken from third-party databases. Investment activity (deals, co-investors) is not yet recorded.
- https://www.boehringer-ingelheim-venture.com/name, is_investor, hq_country, hq_city, invests_in_geographies, thesis_quote, thesis_quote_page, description, portfolio_count, status, confidence
- https://www.boehringer-ingelheim-venture.com/about-uslayer, type, stage_min, stage_max, sectors, founded, aum
- https://www.boehringer-ingelheim-venture.com/teampeople
Is this record wrong or stale? Report a mistake — it reaches us directly, no email address to look up.
Record 1201 · added 2026-08-28 · link last verified 2026-10-21 · confidence high
Similar investors
- BASF Venture Capital GmbHCorporate venture · Seed – Series B · Ludwigshafen, Germany
- Beiersdorf Venture CapitalCorporate venture · Series A – Growth · Hamburg, Germany
- EnBW New VenturesCorporate venture · Series A · Karlsruhe, Germany
- MAHLE New Ventures GmbHCorporate venture · Stuttgart, Germany
- Siemens Financial ServicesCorporate venture · Growth · Munich, Germany
- adesso venturesCorporate venture · Pre-seed – Seed · Germany